Veritas In Silico Inc. (130A.T)
Tokyo · JPY · Healthcare · Biotechnology
¥300 (-2.28%) as of
Key statistics
- Market cap
- 1.95B
- EPS (TTM)
- -96.79
- Dividend yield
- 0.00%
- 52-week range
- 295.00 – 793.00
- Beta
- -0.27
- Revenue (TTM)
- 84.42M
- Profit margin
- 0.00%
- Volume
- 31.00k
About Veritas In Silico Inc.
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company has commercialization agreement with Liverpool ChiroChem for the mRNA-targeted drug discovery and development. Veritas In Silico Inc. was incorporated in 2016 and is based in Shinagawa, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Shinagawa, Japan
- Employees
- 19
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.